Technology evaluation: ISIS-3521

Current Opinion in Molecular Therapeutics

Volumn 1, Issue 3, 1999, Pages 393-398

  Li, Kai ^a   Zhang, Jia ^b   Sirois, Pierre ^c   Hu, Yinghe ^d  

^a 1621 e King/Drew Medical Center ^*  (United States)

^b Memory Pharmaceutical Inc   (United States)

^c UNIVERSITÉ DE SHERBROOKE   (Canada)

^d Hugene Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; ISIS 3521; ISIS 9606; PROTEIN KINASE C; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER INHIBITION; CLINICAL TRIAL; DRUG ACTIVITY; DRUG BINDING; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; DRUG SCREENING; DRUG SELECTIVITY; DRUG SYNTHESIS; DRUG TARGETING; DRUG TOLERABILITY; ENZYME INHIBITION; HUMAN; NONHUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; SHORT SURVEY; TISSUE DISTRIBUTION;

ANIMALS; BIOLOGICAL AVAILABILITY; CANCER VACCINES; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME INHIBITORS; GENE THERAPY; HEMATOLOGIC DISEASES; HUMANS; ISOENZYMES; MICE; MICE, NUDE; NEOPLASM PROTEINS; NEOPLASMS; OLIGODEOXYRIBONUCLEOTIDES, ANTISENSE; ORGAN SIZE; PATENTS; PROTEIN KINASE C; PROTEIN KINASE C-ALPHA; STRUCTURE-ACTIVITY RELATIONSHIP; THIONUCLEOTIDES; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

ANIMALIA;

EID: 0033031034     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (42)

1. Dean NM, McKay R: Inhibition of PKC-alpha expression in mice after systemic administration of phosphorothioate antisense oligodeoxynucleotides. Proc Natl Acad Sci USA (1994) 91:11762-11766.
2. Dean NM, McKay R, Miraglia L, Geiger T, Müller M, Fabbro D, Bennett CF: Antisense oligonucleotides as inhibitors of signal transduction: Development from research tools to therapeutic agents. Biochem Soc Trans (1996) 24:623-629.
3. Monia BP, Johnston JF, Geiger T, Muller M, Fabbro D: Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase. Nat Med (1996) 2:668-675.
4. McKay R, Cummins LL, Graham MJ, Lesnik, EA, Owens SR, Winniman M, Dean NM: Enhanced activity of an antisense oligonucleotide targeting murine protein kinase C-alpha by the Incorporation of 2′-O-propyl modifications. Nucleic Acids Res (1996) 24:411-417.
5. Dean NM, McKay R, Miraglia L, Howard R, Cooper S, Giddings J, Nicklin P, Meister L, Zeil R, Geiger T, Muller M, Fabbro D: Inhibition of growth of human tumor cell lines In nude mice by an antisense oligonucleotide inhibitor of protein kinase C-alpha expression. Cancer Res (1996) 56:3499-3507.
6. Yazaki T, Ahmad S, Chahlavi A, Zylber-Katz E, Dean NM, Rabkin SD, Martuza RL, Glazer RI: Treatment of glioblastoma U-87 by systemic administration of an antisense protein kinase C-alpha phosphorothioate oligodeoxynucleotide. Mol Pharmacol (1996) 50:236-242.
7. Levesque L, Dean NM, sasmor H, Crooke ST: Antisense oligonucleotides targeting human protein kinase C-alpha inhibit phorbol ester-induced reduction of bradykinin-evoked calcium mobilization in A549 cells. Mol Pharmacol (1997) 51:209-216.
8. Monia BP, Johnston JF, Sasmor H, Cummins LL: Nuclease resistance and antisense activity of modified oligonucleotdes targeted to Ha-ras. J Biol Chem (1996) 271:14533-14540.
9. Ho PT, Parkinson DR: Antisense oligonucleotides as therapeutics for malignant diseases. Semin Oncol (1997) 24:187-202.
10. ISIS and CIBA: Vision's drug for CMV retinitis receives advisory committee recommendation for approval. Press Release (1998) July 22.
11. Alahari SK, DeLong R, Fisher MH, Dean NM, Viliet P, Juliano RL: Novel chemically modified oligonucleotides provide potent inhibition of P-glycoprotein expression. J Pharmcol Exp Ther (1998) 286:419-428.
12. Campbell MJ, Dawson M, Koeffler HP: Growth inhibition of DU-145 prostate cancer cells by a Bcl-2 antisense oligonucleotide is enhanced by N-(2-hydroxyphenyl)all-trans retinamide. Br J Cancer (1998) 77:739-44.
13. McGraw K, McKay R, Miraglia L, Boggs RT, Pribble JP, Muller M, Geiger T, Fabbro D, Dean NM: Antisense oligonucleotides inhibitors of isozymes of protein kinase C: in vitro and in vivo activity, and clinical development as anti-cancer therapeutics. Anticancer Drug Des (1997) 12:315-326.
14. Denham DW, Franz MG, Denham W, Zervos EE, Gower WR Jr, Rosemurgy AS, Norman J: Directed antisense therapy confirms the role of protein kinase C-alpha in the tumorigenicity of pancreatic cancer. Surgery (1998) 124:218-223.
15. Morse-Gaudio M, Connolly JM, Rose DP: Protein kinase C and its isoforms in human breast cancer cells: relationship to the invasive phenotype. Int J Oncol (1998) 12:1349-1354.
16. Liu B, Maher RJ, De Jonckheere JP, Popat RU, Stojakovic S, Hannun YA, Porter AT, Honn KV: 12(S)-HETE increases the motility of prostate tumor cells through selective activation of PKC alpha. Adv Exp Med Biol (1997) 4008:707-718.
17. Tortora G, Caputo R, Damiano V, Bianco R, Pepe S, Bianco AR, Jiang Z, Agrawal S, Ciardiello F: Synergistic inhibition of human cancer cell growth by cytotoxic drugs and mixed backbone antisense oligonucleotide targeting protein kinase A. Proc Natl Acad Sci USA (1997) 94:12586-12591.
18. Gorospe M. Holbrook NJ: Role of p21 in prostaglandin A2-mediated cellular arrest and death. Cancer Res (1996) 56:475-479.
19. Pratt MA, Krajewski S, Menard M, Krajewska M, Macleod H, Reed JC: Estrogen withdrawal-Induced human breast cancer tumour regression in nude mice is prevented by Bcl-2. FEBS Lett (1998) 440:403-408
20. Yan DH: Targeting human breast cancer cells that overexpress HER-2/neu mRNA by an antisense iron responsive element. Biochem Biophys Res Commun (1998) 246:353-358.
21. Fakler B, Herlitze S, Amthor B, Zenner HP, Ruppersberg JP: Short antisense oligonucleotide-mediated inhibition is strongly dependent on oligo length and concentration but almost independent of location of the target sequence. J Biol Chem (1994) 269:16187-16194.
22. McKay RA, Miraglia LJ, Cummins LL, Owens SR, Sasmor H, Dean NM: Characterization of a potent and specific class of antisense oligonucleotide inhibitor of human protein kinase C-α expression. J Biol Chem (1999) 274:1715-1722.
23. Baltuch GH, Dooley NP, Villemure JG, Yong VW: Protein kinase C and growth regulation of malignant gliomas. Can J Neurol Sci (1995) 22:264-271.
24. Lee YS, Dlugosz, AA, McKay R, Dean NM, Yuspa SH: Definition by specific Antisense oligonucleotides of a role for protein kinase C alpha in expression of differentiation markers in normal and neoplastic mouse epidermal keratinocytes. Mol Carcinog (1997) 18:44-53.
25. Bianchi A, Mariani S, Beggiato E, Borrione P, Peola S, Boccadoro M, Pileri A, Massaia M: Distribution of T-cell signalling molecules in human myeloma. Br J Haemotol (1997) 97:815-820.
26. Suga K, Sugimoto I, Ito H, Hashimoto E: Down-regulation of protein kinase C-alpha detected in human colorectal cancer. Biochem Mol Biol Int (1998) 44:523-528.
27. Bennett CF, Mirejovsky D, Crooke RM, Tsai YJ, Felgner J, Sridhar CN, Wheeler CJ, Felgner PL: Structural requirements for cationic lipid mediated phosphorothioate oligonucleotides delivery to cells in culture. J Drug Targeting (1998) 5:149-162.
28. Mohuczy D, Gelband CH, Phillips MI: Antisense inhibition of AT1 receptor in vascular smooth muscle cells using adeno-associated virus-based vector. Hypertension (1999) 33:354-359.
29. Lorenz P, Baker BF, Bennett CF, Spector DL: Phosphorothioate Antisense oligonucleotides induce the formation of nuclear bodies. Mol Biol Cell (1998) 9:1007-1023.
30. Bijsterbosch MK, Manoharan M, Rump ET, De Vrueh RL, van Veghel R, Tivel KL, Biessen EA, Bennett CF, Cook PD, van Berkel TJ: In vivo fate of phosphorothioate antisense oligodeoxynucleotides: predominant uptake by scavenger receptor on endothelial liver cells. Nucleic Adds Res (1997) 25:3290-3296.
31. Woolf TM, Jennings CG, Rebagliate M, Melton DA: The stability, toxicity and effectiveness of unmodified and phosphorothioate antisense oligodeoxynucleotides in Xenopus oocytes and embryos. Nucleic Add Res (1990) 18:1763-1769.
32. Offermann MK, Zimring J, Mellits KH, Hagan MK, Shaw R, Medford RM, Mathews MB, Goodboum S, Jagus R: Activation of the double-stranded-RNA-activated protein kinase and induction of vascular cell adhesion molecule-1 by poly (1).poly (C) in endothelial cells. Eur J Biochem (1995) 232:28-36.
33. Zangemeister-Wittke U, Schenker T, Luedke GH, Stahel RA: Synergistic cytotoxicity of bcl-2 antisense oligodeoxynucleotides and etoposide, doxorubicin and cisplatin on small-cell lung cancer cell lines. Br J Cancer (1998) 78:1035-1042.
34. Roh H, Pippin J, Boswell C, Drebin JA: Antisense oligonucleotides specific for the HER2/neu oncogene inhibit the growth of human breast carcinoma cells that overexpress HER2/neu. J Surg Res (1998) 77:85-90.
35. Park IC, Park MJ, Lee SH, Choe TB, Jang JJ, Hong SI: Increased susceptibility of the c-Myc overexpressing cell line, SNU-16, to TNF-alpha. Cancer Lett (1998) 125:17-23.
36. Skilling JS, Squatrito RC, Connor JP, Niemann T, Buller RE: p53 gene mutation analysis and antisense-mediated growth inhibition of human ovarian carcinoma cell lines. Gynecol Oncol (1996) 60:72-80.
37. Fomaro M, Tallini G, Zheng DQ, Flanagan WM, Manzotti M, Languino LR: p27(kip1) acts as a downstream effector of and is coexpressed with the beta1C integrin in prostatic adenocarcinoma. J Clin Invest (1999) 103:321-329.
38. Irminger-Finger I, Soriano JV, Vaudan G, Montesano R, Sappino AP: In vitro repression of Brca1-associated RING domain gene, Bard1, induces phenotypic changes in mammary epithelial cells. J Cell Biol (1998) 143:1329-1339.
39. Boutwell RK, Verma AK, Ashendel CL, Astrup E: Mouse skin: a useful model system for studying the mechanism of chemical carcinogenesis. Carcinog Compr Surv (1982) 7:1-12.
40. Yin DL, Pu L, Pei G: Antisense oligonucleotide to Insulin-like growth factor II induces apoptosis in human ovarian cancer AO cell line. Cell Res (1998) 8:159-165.
41. Kissil JL, Kimchi A: Death-associated proteins: from gene identification to the analysis of their apoptotic and tumour suppressive functions. Mol Med Today (1998) 4:268-274.
42. Holmlund JT, Maria BP, Kwoh TJ, Dorr FA: Toward antisense oligonucleotide therapy for cancer: Isis compounds in clinical development. Curr Opin Mol Ther (1999) 1 (3):372-385.